"We are excited to be working with Dr, Adams in this effort," said Bill Edelman, CEO of TyRx Pharma, "The study results begin the validation of our AIGISRx DEB concept. Despite intensive therapeutic efforts spanning more than four decades, capsular contracture continues to be the most common, perplexing, and frustrating problem associated with mammary augmentation."
Although the exact etiology of capsular contracture is unknown, subclinical infection is widely believed to be the major contributor. Irrigation is a standard procedure in most clinical practices involving breast implants. "Dr. Adams is one of a handful of plastic surgeons actively studying the relationship between subclinical infection, inflammation, and capsular contracture. The data to be presented show that bacterial contamination can have a direct effect on capsular contracture," said Arikha Moses, Ph.D., CSO of TyRx Pharma.
This notice follows TyRx's August 9th announcement of Mark Citron joining TyRx as Vice President, Clinical and Regulatory Affairs.
About TyRx Pharma, Inc.
TyRx Pharma, Inc., an ISO 9001:2000 and ISO 13485:2003 certified
medical device manufacturer, commercializes combination medical products
utilizing novel biomaterials technology licensed exclusively from Rutgers,
The State University of New Jersey. Additionally, TyRx has exclusively
licensed from Baylor College of Medicine and The University of Texas M. D.
Anderson Cancer Center product patents and associated technologies to
address the problem of postsurgical nosocomial infection. TyRx is deploying
its capabilities across a broad range of combination products. The
combination products sector (products incorpor
|SOURCE TyRx Pharma, Inc.|
Copyright©2007 PR Newswire.
All rights reserved